Literature DB >> 24633447

MDMA effects consistent across laboratories.

Matthew G Kirkpatrick1, Matthew J Baggott, John E Mendelson, Gantt P Galloway, Matthias E Liechti, Cédric M Hysek, Harriet de Wit.   

Abstract

RATIONALE: Several laboratories have conducted placebo-controlled drug challenge studies with 3,4-methylenedioxymethamphetamine (MDMA), providing a unique source of data to examine the reliability of the acute effects of the drug across subject samples and settings. We examined the subjective and physiological responses to the drug across three different laboratories and investigated the influence of prior MDMA use.
METHODS: Overall, 220 healthy volunteers with varying levels of previous MDMA experience participated in laboratory-based studies in which they received placebo or MDMA orally (1.5 mg/kg or 125-mg fixed dose) under double-blind conditions. Cardiovascular and subjective effects were assessed before and repeatedly after drug administration. The studies were conducted independently by investigators in Basel, San Francisco, and Chicago.
RESULTS: Despite methodological differences between the studies and differences in the subjects' drug use histories, MDMA produced very similar cardiovascular and subjective effects across the sites. The participants' prior use of MDMA was inversely related to feeling "Any Drug Effect" only at sites testing more experienced users.
CONCLUSIONS: These data indicate that the pharmacological effects of MDMA are robust and highly reproducible across settings. There was also modest evidence for tolerance to the effects of MDMA in regular users.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633447      PMCID: PMC4161650          DOI: 10.1007/s00213-014-3528-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  Replication studies: Bad copy.

Authors:  Ed Yong
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

2.  Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.

Authors:  G J H Dumont; F C G J Sweep; R van der Steen; R Hermsen; A R T Donders; D J Touw; J M A van Gerven; J K Buitelaar; R J Verkes
Journal:  Soc Neurosci       Date:  2009       Impact factor: 2.083

3.  Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department.

Authors:  K Sherlock; K Wolff; A W Hay; M Conner
Journal:  J Accid Emerg Med       Date:  1999-05

4.  A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans.

Authors:  Matthew G Kirkpatrick; Erik W Gunderson; Audrey Y Perez; Margaret Haney; Richard W Foltin; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2011-06-30       Impact factor: 4.530

Review 5.  Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.

Authors:  A C Parrott
Journal:  J Psychopharmacol       Date:  2005-01       Impact factor: 4.153

6.  Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.

Authors:  Kate M Morefield; Michael Keane; Peter Felgate; Jason M White; Rodney J Irvine
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

7.  Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others.

Authors:  Gillinder Bedi; David Hyman; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2010-10-14       Impact factor: 13.382

8.  Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.

Authors:  Michael H Baumann; Robert D Clark; Richard B Rothman
Journal:  Pharmacol Biochem Behav       Date:  2008-03-04       Impact factor: 3.533

9.  Prediction of psilocybin response in healthy volunteers.

Authors:  Erich Studerus; Alex Gamma; Michael Kometer; Franz X Vollenweider
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Priming of social distance? Failure to replicate effects on social and food judgments.

Authors:  Harold Pashler; Noriko Coburn; Christine R Harris
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

View more
  20 in total

1.  Using 'hug drugs' to understand affiliative behavior: the value of the social neurochemistry perspective. Commentary on: 'Ecstasy' as a social drug: MDMA preferentially affects responses to emotional stimuli with social content by Wardle, Kirkpatrick, and de Wit (2014).

Authors:  Ian D Roberts; Baldwin M Way
Journal:  Soc Cogn Affect Neurosci       Date:  2014-05-01       Impact factor: 3.436

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 3.  MDMA for the treatment of mood disorder: all talk no substance?

Authors:  Rachel Patel; Daniel Titheradge
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

Review 4.  Progress and promise for the MDMA drug development program.

Authors:  Allison A Feduccia; Julie Holland; Michael C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2017-11-20       Impact factor: 4.530

5.  MDMA: a social drug in a social context.

Authors:  Matthew G Kirkpatrick; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2014-10-05       Impact factor: 4.530

6.  Potential for limited reinforcing and abuse-related subjective effects of intranasal oxytocin.

Authors:  Sean B Dolan; Meredith S Berry; Patrick S Johnson; Matthew W Johnson
Journal:  J Psychopharmacol       Date:  2019-09-02       Impact factor: 4.153

7.  Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies.

Authors:  Erich Studerus; Patrick Vizeli; Samuel Harder; Laura Ley; Matthias E Liechti
Journal:  J Psychopharmacol       Date:  2021-03-30       Impact factor: 4.153

8.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 9.  The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Authors:  Anya K Bershad; Melissa A Miller; Matthew J Baggott; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2016-08-25       Impact factor: 4.153

10.  Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment.

Authors:  Anna Borissova; Bart Ferguson; Matthew B Wall; Celia Ja Morgan; Robin L Carhart-Harris; Mark Bolstridge; Michael Ap Bloomfield; Tim M Williams; Amanda Feilding; Kevin Murphy; Robin J Tyacke; David Erritzoe; Lorna Stewart; Kim Wolff; David Nutt; H Valerie Curran; Will Lawn
Journal:  J Psychopharmacol       Date:  2020-06-15       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.